(VIANEWS) – Mercury General Corporation (MCY), Catalyst Pharmaceuticals (CPRX), CubeSmart (CUBE) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Mercury General Corporation (MCY)
29.3% sales growth and 14.04% return on equity
Mercury General Corporation, together with its subsidiaries, engages in writing personal automobile insurance in the United States. It also writes homeowners, commercial automobile, commercial property, mechanical protection, fire, and umbrella insurance. The company's automobile insurance products cover collision, property damage, bodily injury, comprehensive, personal injury protection, underinsured and uninsured motorist, and other hazards; and homeowners' insurance products cover dwelling, liability, personal property, fire, and other hazards. It sells its policies through a network of independent agents, 100% owned insurance agents, and direct channels in Arizona, California, Florida, Georgia, Illinois, Nevada, New Jersey, New York, Oklahoma, Texas, and Virginia. The company was founded in 1961 and is headquartered in Los Angeles, California.
Earnings Per Share
As for profitability, Mercury General Corporation has a trailing twelve months EPS of $3.89.
PE Ratio
Mercury General Corporation has a trailing twelve months price to earnings ratio of 13.57. Meaning, the purchaser of the share is investing $13.57 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.04%.
Sales Growth
Mercury General Corporation’s sales growth is 22.5% for the current quarter and 29.3% for the next.
2. Catalyst Pharmaceuticals (CPRX)
20.5% sales growth and 14.55% return on equity
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.
Earnings Per Share
As for profitability, Catalyst Pharmaceuticals has a trailing twelve months EPS of $0.63.
PE Ratio
Catalyst Pharmaceuticals has a trailing twelve months price to earnings ratio of 24.16. Meaning, the purchaser of the share is investing $24.16 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.55%.
Volume
Today’s last reported volume for Catalyst Pharmaceuticals is 817840 which is 36.47% below its average volume of 1287390.
3. CubeSmart (CUBE)
13.3% sales growth and 14.24% return on equity
CubeSmart is a self-administered and self-managed real estate investment trust. The Company's self-storage properties are designed to offer affordable, easily accessible and secure storage space for residential and commercial customers. According to the 2020 Self-Storage Almanac, CubeSmart is one of the top three owners and operators of self-storage properties in the United States.
Earnings Per Share
As for profitability, CubeSmart has a trailing twelve months EPS of $1.81.
PE Ratio
CubeSmart has a trailing twelve months price to earnings ratio of 24.32. Meaning, the purchaser of the share is investing $24.32 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.24%.
Previous days news about CubeSmart(CUBE)
- Are options traders betting on a big move in cubesmart (cube) stock?. According to Zacks on Wednesday, 10 July, "Clearly, options traders are pricing in a big move for CubeSmart shares, but what is the fundamental picture for the company? ", "Currently, CubeSmart is a Zacks Rank #3 (Hold) in the REIT and Equity Trust – Other industry that ranks in the Bottom 28% of our Zacks Industry Rank. "
4. Merit Medical Systems (MMSI)
8% sales growth and 8.45% return on equity
Merit Medical Systems, Inc. manufactures and markets disposable medical devices for interventional, diagnostic, and therapeutic procedures in cardiology, radiology, oncology, critical care, and endoscopy. The company operates in two segments, Cardiovascular and Endoscopy. It provides peripheral intervention products for the diagnosis and treatment of diseases in peripheral vessels and organs; and cardiac intervention products, such as access, angiography, hemostasis, intervention, fluid management, electrophysiology and cardiac rhythm management, and hemodynamic monitoring to treat various heart conditions. The company also offers custom procedural solutions that include critical care products, disinfection protection systems, syringes, swab and collection systems, manifold kits, and trays and packs; coated tubes and wires; and sensor components for microelectromechanical systems. In addition, it provides pulmonary products that consist of laser-cut tracheobronchial stents, advanced over-the-wire and direct visualization delivery systems, and dilation balloons; gastroenterology products; and kits and accessories for endoscopy and bronchoscopy procedures. The company sells its products to hospitals and alternate site-based physicians, technicians, and nurses through direct sales force, distributors, original equipment manufacturer partners, or custom procedure tray manufacturers in the United States and internationally. The company was incorporated in 1987 and is headquartered in South Jordan, Utah.
Earnings Per Share
As for profitability, Merit Medical Systems has a trailing twelve months EPS of $1.74.
PE Ratio
Merit Medical Systems has a trailing twelve months price to earnings ratio of 50.11. Meaning, the purchaser of the share is investing $50.11 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.45%.
Sales Growth
Merit Medical Systems’s sales growth is 7.8% for the current quarter and 8% for the next.
Moving Average
Merit Medical Systems’s worth is above its 50-day moving average of $81.72 and way higher than its 200-day moving average of $75.26.
Volume
Today’s last reported volume for Merit Medical Systems is 423650 which is 15.32% above its average volume of 367349.
5. U.S. Physical Therapy (USPH)
7.6% sales growth and 6.47% return on equity
U.S. Physical Therapy, Inc., through its subsidiaries, operates outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries. The company operates through two segments, Physical Therapy Operations and Industrial Injury Prevention Services. It offers industrial injury prevention services, including onsite injury prevention and rehabilitation, performance optimization, post-offer employment testing, functional capacity evaluations, and ergonomic assessments through physical therapists and specialized certified athletic trainers for Fortune 500 companies, and other clients comprising insurers and their contractors. The company was founded in 1990 and is based in Houston, Texas.
Earnings Per Share
As for profitability, U.S. Physical Therapy has a trailing twelve months EPS of $1.16.
PE Ratio
U.S. Physical Therapy has a trailing twelve months price to earnings ratio of 79.53. Meaning, the purchaser of the share is investing $79.53 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.47%.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on May 22, 2024, the estimated forward annual dividend rate is 1.76 and the estimated forward annual dividend yield is 1.91%.
6. Primerica (PRI)
5.3% sales growth and 28.56% return on equity
Primerica, Inc., together with its subsidiaries, provides financial products to middle income households in the United States and Canada. The company operates in three segments: Term Life Insurance; Investment and Savings Products; and Corporate and Other Distributed Products. It underwrites individual term life insurance products. The company also provides mutual funds and various retirement plans, managed investments, variable and fixed annuities, fixed indexed annuities, and segregated funds. In addition, it offers auto and homeowners' insurance, home automation solutions, and mortgage loans; ID theft defense services; and insurance products, including supplemental medical and dental, accidental death, and disability for small businesses. Further, the company provides prepaid legal services that assist subscribers with legal matters, such as drafting wills, living wills and powers of attorney, trial defense, and motor vehicle-related matters. It distributes and sells its products through licensed sales representatives. Primerica, Inc. was founded in 1927 and is headquartered in Duluth, Georgia.
Earnings Per Share
As for profitability, Primerica has a trailing twelve months EPS of $16.42.
PE Ratio
Primerica has a trailing twelve months price to earnings ratio of 14.17. Meaning, the purchaser of the share is investing $14.17 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 28.56%.
